Jeffrey Conn

Scanning of a human brain by X-rays
February 12, 2015

Grant spurs schizophrenia research

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.

By Bill Snyder
August 7, 2014

Conn lands Javits Neuroscience Investigator award

Vanderbilt University’s P. Jeffrey Conn, Ph.D., has won a Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke for discoveries that could lead to new treatments for anxiety, schizophrenia and other brain disorders.

By Bill Snyder
June 19, 2014

Hamm’s lasting impact commended at Flexner Discovery Lecture

By Bill Snyder
neurons
March 13, 2014

‘Missing link’ may spur new brain disorder drugs

Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

By Bill Snyder
brain illustration
January 14, 2013

AstraZeneca, VU collaborate to develop new treatments for major brain disorders

AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.

By Bill Snyder
November 29, 2012

Record number elected AAAS fellows

Seventeen members of Vanderbilt University’s faculty have been elected fellows of the American Association for the Advancement of Science (AAAS) this year.

By Bill Snyder
October 18, 2012

Nobel in Chemistry reveals VU ties that bind

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners.
By Bill Snyder
September 21, 2012

VU, Bristol-Myers to collaborate on Parkinson’s therapies

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.
By Bill Snyder
July 17, 2012

Insights for neuroscience drug discovery

When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects.
By Leigh MacMillan
April 6, 2012

Minds wide open: Neuroscience at Vanderbilt

Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience.
By Bill Snyder
September 30, 2011

Drug-like molecules aimed at improving treatment of Parkinson’s

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.
By Bill Snyder
March 11, 2011

Neuroscience drug discovery center opens at Vanderbilt

Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.
By Bill Snyder
1 2 3